Viridian Therapeutics, Inc.DE (VRDN) Institutional Ownership

Ownership Summary

Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) has 225 institutional investors with active 13F positions as of December 2025.

• They owned 126.8% of outstanding stock in December 2025, up from 114.8% the prior quarter.
• They increased total shares held in Viridian Therapeutics, Inc.\DE by 23.02% from the prior quarter, while the number of investors in VRDN increased 26.4% year over year.
• Of these 225 funds, 159 grew their exposure to Viridian Therapeutics, Inc.\DE, 43 cut back, and 23 maintained positions.
• Altogether, these fund groups held 103.71Mn shares in VRDN by December 2025, up by 19.4Mn shares quarter on quarter, and up 10.72Mn shares year over year.
• FMR LLC holds the largest position in VRDN at 15.38Mn shares as of December 31, 2025, or 18.8% of shares outstanding.
• Top purchasers of VRDN stock for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (4.17Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.21Mn), Bellevue Group AG (2.37Mn), BALYASNY ASSET MANAGEMENT L.P. (1.81Mn), Paradigm Biocapital Advisors LP (1.71Mn).
• Leading sellers of Viridian Therapeutics, Inc.\DE shares for the quarter ending December 2025 were PERCEPTIVE ADVISORS LLC (1.87Mn), Avoro Capital Advisors LLC (1.5Mn), Deep Track Capital, LP (1.13Mn), JENNISON ASSOCIATES LLC (1.13Mn), MARSHALL WACE, LLP (1.11Mn).
• Per Business Quant, the top 10 investors in VRDN for the quarter ending December 2025 include FMR LLC (15.38Mn), BlackRock, Inc. (7.83Mn), Bellevue Group AG (6.73Mn), State Street Corp (4.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.17Mn), Fairmount Funds Management LLC (3.91Mn), Venrock Adviser, LLC (3.88Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.21Mn), Paradigm Biocapital Advisors LP (3.15Mn), WELLINGTON MANAGEMENT GROUP LLP (3.08Mn).